Anti-vascular endothelial growth factor

Not available outside of the UK & Ireland.

Application

Anti-Vascular Endothelial Growth Factor Receptor 2 antibody may be used in immunoblotting at a working concentration of 0.1-0.2 µg/ml. For flow cytometry the recommended concentration is 3-10 µg/ml. The immunohistochemistry of cells and tissues, a working concentration of 5-15 µg/ml may be used. For neutralization reactions, ND50 of 0.1-0.3 µg/ml is recommended.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

Vascular endothelial growth factors receptors (VEGF Rs) are receptor tyrosine kinases that bind to VEGF that plays important role in embryonic vasculogenesis, angiogenesis and homeostasis. VEGF R2 has the ability to form heterodimers with VEGF R1 and VEGF R3. The binding of VEGF to VEGF R2 results in activation of tyrosine amino acids of the cytoplasmic tail of the receptor. This interaction results in the activation of MAPK, PI3K, PKC, FAK and Src kinase pathways. The biological roles of VEGF R2 include in epithelial cell growth, proliferation, survival, migration and vascular permeability and angiogenesis. Due to its role in promoting migration and angiogenesis, VEGF R2 has been implicated in breast and prostate cancer Anti-Vascular Endothelial Growth Factor Receptor-2 recognizes mouse VEGF R2.

Immunogen

purified recombinant mouse VEGF R2 extracellular domain expressed in NSO cells.

Physical form

Lyophilized from a 0.2 µm filtered solution in phosphate buffered saline containing carbohydrates.

Specificity

The antibody has the ability to neutralize the biological activity of recombinant mouse VEGF R2. It demonstates approximately 40% cross-reactivity with recombinant human VEGF R2, 2% cross-reactivty with recombinant mouse VEGF R1, and no cross-reactivity with recombinant human VEGF R1 and VEGF R3.